morning, everyone. and Thank good you, Tina
XX% TEPEZZA and $X.X year Our year million, detail of our of then provide performance. more which record We EBITDA into sales billion, launch our Horizon. driven investment growth fourth tremendous and net quarter highlights capped adjusted the I’ll results off another significant $XXX full review for preparation. of included KRYSTEXXA on by progress achieve
EBITDA this our strong business investment, adjusted for double-digit underlying year. growth the generated Excluding
in excitement next on day Journal This share was TEPEZZA Medicine our nearly and TED, the is New the PDUFA the has January Phase by level of results. more the of demand date. Eye of biologic X approved TEPEZZA and on Publication for in trial Disease ahead incredible new it I’ll followed our month England for months XXst, market. shortly. We’ve Thyroid seen or the first two
methotrexate. has KRYSTEXXA the seen This rate was doubled KRYSTEXXA, uncontrolled we driver, biologic in the better. XX% announced its key with complete With that line roughly of response dataset MIRROR X program. you trial consistent other result from use and a our rate with or label with a gout our response It XX% open growth Phase third rate results top demonstrated when complete XX%
Based on increased expectations further existing KRYSTEXXA year. nephrology, more for continued than and we growth and our of adoption of continued earlier net sales penetration estimates KRYSTEXXA in US with $X billion peak accounts, this methotrexate, new
TEPEZZA estimate net than billion. We for to $X peak sales also the US increase more
capital improved XXXX, and significantly maturities by down in reducing more of our than our expense extending We $XXX net XX%. debt paying million our structure gross interest annualized debt,
full in Paul in of $X.XX in detail. year expand of sheet balance billion go and medicine stage pipeline. issued this morning, our $XXX $XXX will adjusted acquire to great net through EBITDA. strong And development a XXXX license or to to puts more Our in million this sales to million billion we position us guidance $X.X
double-digit TEPEZZA of Horizon targets fastest timeframe and strong growth earnings one As believe during primarily to we and the our margin looked by at We we space. make the XXXX net expansion and expect KRYSTEXXA. companies will growth in the our operating sales growing significant of to XXXX generate beyond, over growth XXXX double-digit
a outcome TEPEZZA a X of results that in Last our for a year achieving the TEPEZZA. with proptosis for Phase dramatic commentary medicines trial I’ll landmark our now year provide patients of February versus placebo. key improvement certainly additional with primary in with began release XX% X% beginning of was
We meeting with received committee the December, and following expectations early advisory we ahead highly success submitted of our January at XXst. a in FDA BLA July approval on
We’re patients approved disease. this and treat first to Disease Thyroid and be to rare vision-threatening pleased Eye medicine provide the to disfiguring company
The privilege. is to physician launch off lengths Our feedback Horizon at healthcare our make and received to a to not priority, exemplifies strong have to patient just start. and vision go we incredible a a
surgeon first In we’re fact, surgery, X following TED many complex eye our business are program is TEPEZZA alignment first be surgery, And education there a would more and like better that. patient this into was decided scheduled to physician option. which stories
the interest TEPEZZA certainly for on than approval. well Xth, the started promise significant also efforts we reflects to due less treatment approval. two us started February weeks before It’s first after market of the Those day patient are substantial education when momentous This TEPEZZA.
team last educating XXX% TEPEZZA in the has and stakeholders. market building July, Our relationships been since key key
in is key Our focused four areas. strategy for TEPEZZA
medicine was approved the no establish even given care. which thoroughly very simplify it First, of market were patient structure long there and defined, the has standard or frustrating been journey,
Second, centers as or patient well educate a payers. TED including patients, infusion as sites care on all and TEPEZZA of organizations, stakeholders physicians, advocacy
patient-centric Third, access which TEPEZZA facilitate so this for referral launch establishing to and our support important with by the infusion is site care medicine. network, comprehensive model high toxic of fourth,
our in We progress. and has physician our X,XXX investigations excellent at to early month called of than queue, XXX PEFs this patient which very still tier about similar on strong date. far enrollment initial are forms we’re in an now over this we’ve indication benefit to expectations or XX% approval, early more launch Since is accounts. top of team or demand. made While prescriptions are their have the PEFs our a
that formularies TED oculoplastic we for delay not XX% ophthalmology surgeons in well strong temporary as this which to PEF and community submitting infusion, formulary very XX day and and a while reimbursement XX access across plans. subject to are are government and interest dynamics, broader TEPEZZA. up priority PEFs to conversion wait demand, indicates subspecialties. code PEFs from physicians majority we number day targets, reflects remain the physicians of payer both commercial significant decisions policy Well have vast or as are the from to the including received day our about commercial Currently The for of
Part we submitted J-code. this Like permanent J-code infused all we will We code, we medicines, into a effect that permanent a with reimbursement application temporary more that for go our October early much With expect launched B Medicare become February in Xst. efficient. on anticipate process should TEPEZZA
payer meeting team in this access targets, time. nearly payer our and point is total nearly coverage positive Our XX% Conversations representing related at scheduled lives. of of XX% have been top with to
Since centers including regional care more national than to infusion has approval, now Our great approves site accounts. made XXX activated team administer as of they’ve accounts coverage. to are and provided Activated payer TEPEZZA progress well. ready
campaigns highly successful. have media Finally, our direct-to-patient and been direct-to-physician
Given of and that to can fact themselves. be TEPEZZA the for population TED, activated of nature vision-threatening disfiguring two-thirds are patients the patient a that ask female, is and this
we’re been [visitorstepezza.com] [ph] not So surprised very that engaged. have
our then site the In been through to rates people more have running fact, XX%, and our been click than dramatically it X%, engagement in or even ad, to centers of of and TEPEZZA. There’s physicians, social standard a industry on from which level Twitter, and than X% significant infusion Instagram. underscores the go patients Facebook percentage high clicked across media exceptionally interest of higher
that the so very is the TEPEZZA. enthusiastic We’re pleased community for about promise
given the than to-date, net in segment, and confident total cover sales are XX% need XX% in significant expectation, We’ll continue increased rheumatology market. $X billion now briefly of orphan very we’ve to fourth success had Based we our represented net US approximately peak sales on more unmet the this early which our quarter. feel
XX%, KRYSTEXXA by was performance driven the increasing with strong our sales vial growth. again driver quarter major net of fourth
exceeded net more with of this $X of than sales growth also expectation again KRYSTEXXA to more year than in our billion the XX%. ending earlier US We growth increased expect XXXX. XX%, We growth peak our full year, target more than XX% year
a continued fantastic affairs the opportunity X-year medical Not addressable this commercial States this lay of of type in Even medicines job X% growth. brand. use XXXX have there’s old for so, patients and the many in only and teams to substantial growth. XXX,XXX a reinvigorating United clinical claim The KRYSTEXXA can of done
of see nephrology increased acceleration last of where of three put space, growth the the in and uptake of continuing a accounts methotrexate of from accounts, areas as new place We expand with year. seeing such increasing KRYSTEXXA KRYSTEXXA, in dedicated salesforce our growth continued efforts KRYSTEXXA to existing we’ve we’re use for and immunomodulators nephrology
external Physicians are when dramatically they it using frequently, as a investigators more methotrexate the XXX% increases rate. two with such KRYSTEXXA. This as XX% immunomodulators response evidence see data methotrexate and demonstrate complete rate of that by continue generated that patient includes used was positive KRYSTEXXA response to
a separate trial adding significant X our that cyclosporine evidence doubling this January, and with the methotrexate top of KRYSTEXXA with resulted response complete to investigator added in seen recently published open to In patients. A azathioprine rate, and the those line MIRROR in response achieved rate clinical methotrexate, of of complete that the XXX% demonstrated also Phase label almost we in XX% results immunomodulators, use from KRYSTEXXA body rate including program. multiple
through before data, with public, reviewed was October digits. year, KRYSTEXXA. physician XXXX, to recently which last our the use immunomodulators We’ve it In data We were has of that low use analyzed understand an the single claims grown results open physician and growth double-digits. label MIRROR early running of the showed in
of stay care. is patients the increases success their patient significantly potentially physician of longer. in KRYSTEXXA KRYSTEXXA for likelihood rate For use on prescribing of response to methotrexate, in higher patients therapy the higher, more This allowing confidence to
strong, in RAVICTI on growth. patients quarter. RAVICTI, disease doses, ACTIMMUNE, Moving indications typically patients a for and new on medicines PROCYSBI rare expanded to many shipping will compliance younger, PROCYSBI as combined grow by treatment which increase Average older. net starting are single-digits improved demand for patient the increased they across lower mid With and driven remained
driven throughout journey. support is diagnosis identification, of patient strategy Our patients and their ongoing by treatment
committee early Phase leading TEPEZZA I’ll clinical in who over discuss with Liz the and in advisory turn the approval. will is Liz? important program integrally R&D Liz our call detail. Clinical our led our Liz, TEPEZZA more to meeting now was and Development success TEPEZZA X the progress Organization.
